

Thomas Zeller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8475889/publications.pdf>

Version: 2024-02-01

91
papers

10,291
citations

46918

47
h-index

48187

88
g-index

91
all docs

91
docs citations

91
times ranked

3089
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful Secondary Endovascular Intervention in Pediatric Patients with Venous Thromboembolic Events. <i>Hamostaseologie</i> , 2022, , .	0.9	0
2	Orbital Atherectomy Prior to Drug-Coated Balloon Angioplasty in Calcified Infrapopliteal Lesions: A Randomized, Multicenter Pilot Study. <i>Journal of Endovascular Therapy</i> , 2022, 29, 874-884.	0.8	9
3	Time for a Standardized Common Femoral Artery Classification System. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 448-449.	0.9	0
4	Individual patient data meta-analysis of patients treated with a heparin-bonded Viabahn in the femoropopliteal artery for chronic limb-threatening ischemia. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	2
5	2-Year Results With a Sirolimus-Eluting Self-Expanding Stent for Femoropopliteal Lesions. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 618-626.	1.1	7
6	Femoropopliteal Drug-coated Balloon Angioplasty: Long-term Results of the Randomized EffPac Trial. <i>Radiology</i> , 2022, , 212622.	3.6	1
7	Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial. , 2022, 1, 100341.		15
8	Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 196-206.	0.9	7
9	Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial. <i>Journal of Endovascular Therapy</i> , 2021, 28, 222-228.	0.8	10
10	Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 368-375.	0.9	55
11	Treatment of Femoropopliteal Lesions With the BioMimics 3D Vascular Stent System: Two-Year Results From the MIMICS-2 Trial. <i>Journal of Endovascular Therapy</i> , 2021, 28, 236-245.	0.8	6
12	The SELUTION SLR, a drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions. <i>Future Cardiology</i> , 2021, 17, 257-267.	0.5	9
13	Modern multidisciplinary team approach is crucial in treatment for critical limb threatening ischemia. <i>Journal of Cardiovascular Surgery</i> , 2021, 62, 124-129.	0.3	3
14	Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC). <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 387-393.	0.6	6
15	Contralateral Stenosis and Echolucent Plaque Morphology are Associated with Elevated Stroke Risk in Patients Treated with Asymptomatic Carotid Artery Stenosis within a Controlled Clinical Trial (SPACE-2). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105940.	0.7	5
16	Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial. <i>Trials</i> , 2021, 22, 665.	0.7	7
17	Real-World Experience With a Paclitaxel-Coated Balloon in Critical Limb Ischemia. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2289-2299.	1.1	12
18	Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions. <i>Journal of Endovascular Therapy</i> , 2020, 27, 683-690.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial. <i>Radiology</i> , 2020, 296, 638-640.	3.6	5
20	Digital Subtraction Angiography Prior to an Amputation for Critical Limb Ischemia (CLI): An Expert Recommendation Statement From the CLI Global Society to Optimize Limb Salvage. <i>Journal of Endovascular Therapy</i> , 2020, 27, 540-546.	0.8	9
21	Balloon Angioplasty of Infrapopliteal Arteries: A Systematic Review and Proposed Algorithm for Optimal Endovascular Therapy. <i>Journal of Endovascular Therapy</i> , 2020, 27, 547-564.	0.8	27
22	Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial. <i>Radiology</i> , 2020, 295, 478-487.	3.6	27
23	Bypass Grafting vs Endovascular Therapy in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Chronic Limb-Threatening Ischemia (CRITISCH Registry). <i>Journal of Endovascular Therapy</i> , 2020, 27, 599-607.	0.8	9
24	Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. <i>Journal of Endovascular Therapy</i> , 2020, 27, 693-705.	0.8	34
25	Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2052-2061.	1.1	24
26	Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial. <i>Journal of Endovascular Therapy</i> , 2020, 27, 276-286.	0.8	17
27	Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial. <i>EuroIntervention</i> , 2020, 15, e1633-e1640.	1.4	16
28	Propensity Score-Adjusted Comparison of Long-Term Outcomes Among Revascularization Strategies for Critical Limb Ischemia. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008097.	1.4	16
29	Paclitaxel and Mortality: The Dose Argument Is Critical. <i>Journal of Endovascular Therapy</i> , 2019, 26, 467-470.	0.8	24
30	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 484-493.	1.1	37
31	Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study. <i>Journal of Endovascular Therapy</i> , 2019, 26, 305-315.	0.8	27
32	Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 667-679.	1.2	111
33	Mortality Not Correlated With Paclitaxel Exposure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2550-2563.	1.2	195
34	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007730.	1.4	10
35	Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 96-105.	0.7	20
36	Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005891.	1.4	166

#	ARTICLE	IF	CITATIONS
37	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. <i>Journal of Endovascular Therapy</i> , 2018, 25, 68-78.	0.8	23
38	One-Year Results of First-Line Treatment Strategies in Patients With Critical Limb Ischemia (CRITISCH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	42
39	Outcomes of dialysis patients with critical limb ischemia after revascularization compared with patients with normal renal function. <i>Journal of Vascular Surgery</i> , 2018, 68, 822-829.e1.	0.6	32
40	Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease—The <sc>ILLUMINATE</sc> Global Study: 12-Month results from a prospective, multicenter, single-arm study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 497-504.	0.7	40
41	A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1541-1551.	6.3	196
42	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005654.	1.4	51
43	Determinants of Long-Term Outcomes and Costs in the Management of Critical Limb Ischemia: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009724.	1.6	113
44	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 945-953.	1.1	71
45	Disease Burden and Clinical Outcomes Following Initial Diagnosis of Critical Limb Ischemia in the Medicare Population. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1011-1012.	1.1	30
46	Safety and Feasibility of Intravascular Lithotripsy for Treatment of Below-the-Knee Arterial Stenoses. <i>Journal of Endovascular Therapy</i> , 2018, 25, 499-503.	0.8	81
47	Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1832-1838.	0.9	60
48	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2113-2123.	1.1	60
49	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	180
50	Endovascular Therapy Versus Bypass Surgery as First-Line Treatment Strategies for Critical Limb Ischemia. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2557-2565.	1.1	77
51	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. <i>Circulation</i> , 2016, 133, 1472-1483.	1.6	426
52	Helical Centerline Stent Improves Patency. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	30
53	Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease. <i>Journal of Endovascular Therapy</i> , 2016, 23, 701-707.	0.8	80
54	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. <i>European Heart Journal</i> , 2016, 37, 1096-1103.	1.0	73

#	ARTICLE	IF	CITATIONS
55	Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2329-2338.	1.2	325
56	Paclitaxel-Coated Balloon in Infrapopliteal Arteries. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1614-1622.	1.1	147
57	Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. <i>Circulation</i> , 2015, 131, 495-502.	1.6	554
58	Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 25-32.	0.9	100
59	Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 102-108.	1.1	230
60	Current practice of first-line treatment strategies in patients with critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2015, 62, 965-973.e3.	0.6	79
61	Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. <i>New England Journal of Medicine</i> , 2015, 373, 145-153.	13.9	558
62	Superiority of Stent-Grafts for In-Stent Restenosis in the Superficial Femoral Artery. <i>Journal of Endovascular Therapy</i> , 2015, 22, 1-10.	0.8	80
63	Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient. <i>Journal of Endovascular Therapy</i> , 2015, 22, 14-21.	0.8	134
64	Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis. <i>Circulation</i> , 2015, 132, 2230-2236.	1.6	128
65	Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease. <i>Journal of Endovascular Therapy</i> , 2015, 22, 727-733.	0.8	82
66	Primary Self-EXPANDING Nitinol Stenting vs Balloon Angioplasty With Optional Bailout Stenting for the Treatment of Infrapopliteal Artery Disease in Patients With Severe Intermittent Claudication or Critical Limb Ischemia (EXPAND Study). <i>Journal of Endovascular Therapy</i> , 2015, 22, 690-697.	0.8	40
67	One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions. <i>Journal of Endovascular Therapy</i> , 2015, 22, 839-846.	0.8	48
68	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 813-820.	1.4	19
69	Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: The Viabahn-25 cm Trial. <i>Journal of Endovascular Therapy</i> , 2014, 21, 765-774.	0.8	51
70	Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Long Femoropopliteal Lesions. <i>Journal of Endovascular Therapy</i> , 2014, 21, 359-368.	0.8	129
71	Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the Complete SE Multicenter Trial. <i>Journal of Endovascular Therapy</i> , 2014, 21, 202-212.	0.8	65
72	IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. <i>Trials</i> , 2014, 15, 63.	0.7	19

#	ARTICLE	IF	CITATIONS
73	The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 10-19.	1.1	346
74	Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 546-554.	0.7	51
75	Lower Extremity Revascularization Using Directional Atherectomy. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 923-933.	1.1	210
76	Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1568-1576.	1.2	327
77	Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, E212-20.	0.7	391
78	Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 274-281.	1.1	109
79	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2417-2427.	1.2	307
80	High-Grade, Non-Flow-Limiting Dissections Do Not Negatively Impact Long-term Outcome After Paclitaxel-Coated Balloon Angioplasty: An Additional Analysis From the THUNDER Study. <i>Journal of Endovascular Therapy</i> , 2013, 20, 792-800.	0.8	74
81	A Prospective Randomized Multicenter Comparison of Balloon Angioplasty and Infrapopliteal Stenting With the Sirolimus-Eluting Stent in Patients With Ischemic Peripheral Arterial Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2290-2295.	1.2	233
82	Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. <i>Journal of Vascular Surgery</i> , 2012, 55, 390-398.	0.6	228
83	Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2012, 60, 587-591.	1.2	152
84	Endovascular Treatment of Common Femoral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 792-798.	1.2	139
85	Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 495-504.	1.4	514
86	Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. <i>European Heart Journal</i> , 2011, 32, 2274-2281.	1.0	162
87	AMS INSIGHT™ Absorbable Metal Stent Implantation for Treatment of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 424-435.	0.9	131
88	Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. <i>New England Journal of Medicine</i> , 2008, 358, 689-699.	13.9	732
89	Two-Year Results after Directional Atherectomy of Infrapopliteal Arteries with the SilverHawk Device. <i>Journal of Endovascular Therapy</i> , 2007, 14, 232-240.	0.8	83
90	Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-term Results From the SIROCCO Trial. <i>Journal of Endovascular Therapy</i> , 2006, 13, 701-710.	0.8	468

#	ARTICLE	IF	CITATIONS
91	Limb Salvage Following Laser-Assisted Angioplasty for Critical Limb Ischemia:Results of the LACI Multicenter Trial. Journal of Endovascular Therapy, 2006, 13, 1-11.	0.8	221